-

01:39:05 PM

IVVD Stock News

IVVD - Invivyd Inc

09/11/23 7:00 AM

Nasdaq : IVVD

clinical trialcovid-19

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that

RHEA-AI

negative

09/06/23 7:00 AM

Nasdaq : IVVD

conferences

Invivyd to Participate in Upcoming Investor Conferences

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences: H.C. Wainwright

RHEA-AI

very negative

09/05/23 7:00 AM

Nasdaq : IVVD

management

Invivyd Appoints William Duke as Chief Financial Officer

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of William Duke as Chief Financial Officer. Mr. Duke will lead

RHEA-AI

neutral

08/10/23 4:01 PM

Nasdaq : IVVD

earnings

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

Reported p ositive initial Phase 1 VYD222 clinical trial data , including favorable safety data and robust serum neutralizing titers from all three dose levels tested Plans to pursue rapid initiation of a 750-participant pivotal clinical trial of VYD222 (CANOPY) that will utilize Day 28 serum

RHEA-AI

neutral

08/03/23 4:01 PM

Nasdaq : IVVD

conferencesearnings

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, August 10, 2023, at 4:30 p.m.

RHEA-AI

very negative

07/27/23 4:01 PM

Nasdaq : IVVD

management

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings

RHEA-AI

neutral

07/17/23 7:00 AM

Nasdaq : IVVD

clinical trialcovid-19

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Continued favorable safety and tolerability profile for all dose levels tested Serum samples from all dose levels tested showed robust neutralization activity against Omicron XBB.1.5, one of the dominant SARS-CoV-2 variants circulating globally Ongoing analysis of serum neutralizing activity and

RHEA-AI

neutral

06/26/23 7:00 AM

Nasdaq : IVVD

covid-19

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

Unique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated clinical trial data from prototype antibody VYD222 and potential future Invivyd mAbs are planned to leverage this EUA pathway using

RHEA-AI

neutral

06/22/23 7:00 AM

Nasdaq : IVVD

clinical trialcovid-19

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to date As predicted by pre-clinical in vitro testing, early serum samples from the first, lowest dose cohort showed strong neutralization activity against Omicron XBB.1.5, one of the dominant

RHEA-AI

neutral

06/01/23 7:00 AM

Nasdaq : IVVD

conferences

Invivyd to Participate at the Jefferies Healthcare Conference

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, chief executive officer of Invivyd, is scheduled to present

RHEA-AI

very negative

IVVD Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websiteadagiotx.com
Security nameInvivyd Inc
SectorManufacturing

About Invivyd Inc

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.